Impact of disease activity outcome measures reporting in the medical records of patients with axial spondyloarthritis on the retention rates of biological treatment: the example of secukinumab use in daily practice in France

• Maxime Dougados,
• Pascal Claudepierre,
• Adeline Ruyssen-Witrand,
• Philippe Goupille,
• Alain Saraux,
• Anne Tournadre,
• Daniel Wendling,
• Cédric Lukas,
• Julien Lucas,
• Emilie Desfleurs

Affiliations

Maxime Dougados

INSERM U1153, Paris, France

Pascal Claudepierre

Rheumatology, Henri Mondor Hospital Rheumatology Service, Creteil, France

Adeline Ruyssen-Witrand

Rheumatology, University Hospital Centre Toulouse, Toulouse, France

Philippe Goupille

Department of Rheumatology, CHRU de Tours, Tours, France

Alain Saraux

16 Rheumatology, CHU Brest, Brest, France

Anne Tournadre

1 Rheumatology, CHU Clermont-Ferrand, Clermont-Ferrand, France

Daniel Wendling

Department of Rheumatology, University Teaching Hospital, CHRU de Besançon, Besancon, France

Cédric Lukas

2 Department of Rheumatology, University Hospital Centre Montpellier, Montpellier, Languedoc-Roussillon, France

Julien Lucas

Biostatistics, RCTs, Lyon, France

Emilie Desfleurs

Medical affairs, Novartis Pharma SAS, Rueil-Malmaison, France